Congenital HIV-1 infection

Infectious Disorders

Updated 01.21.2019
Released 09.24.1994
Expires For CME 01.21.2022

Congenital HIV-1 infection

Authors: Dana Vanino MD, Lucie Henry MS, Kelly J Baldwin MD

See Contributor Disclosures

Editor: Karen L Roos MD FAAN

Congenital HIV-1 infection

In This Article

Quick Link

Introduction

This article includes discussion of congenital HIV-1 infection, human immunodeficiency virus-1 infection, pediatric acquired immunodeficiency syndrome, pediatric AIDS, and vertically acquired HIV-1 infection. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.

Overview

Congenital HIV infection is the transmission of HIV-1 from mother to child, which occurs during or soon after birth. Current prevalence ranges from 1% to 2% in the United States with successful implementation of antiretroviral treatment of mothers during pregnancy. This article includes an overview of congenital HIV-1 infection with updated criteria on reducing transmission through pregnancy and the delivery process, newborn testing for diagnosis, and treatment, including the use of zidovudine prophylaxis.

Key points

	• Congenital HIV infection is maternal-to-child transmission of HIV-1.
	• Prevalence is 1% to 2% in the United States with initiation of antiretroviral treatment of mothers during pregnancy.
	• The disease can be mild to severe, including recurrent infections and neurologic abnormalities.
	• All infants with HIV exposure should receive zidovudine prophylaxis within 6 to 12 hours after delivery.
	• Newborn testing guidelines have been updated and are included for review.

Historical note and terminology

In 1982, soon after the initial descriptions of AIDS in homosexual men, Haitians, hemophiliacs, and intravenous drug users, 4 children with unexplained immunodeficiency and opportunistic infections were reported by the CDC (16). It was not until the following year, however, that the clinical and immunologic features of pediatric AIDS were described in the literature (38; 48).

Clinical manifestations

Presentation and course

The consequences of CNS infection by HIV-1 are highly variable among infected children and can be delayed for several years (07). Neurologic symptoms, however, should not be viewed in isolation from, but associated with, other clinical symptoms and with immunological and virological results: the course of clinical symptoms and biological signs distinguishes a severe infantile mode of evolution from a slowly progressive disease.

At birth, the majority of congenitally HIV-1-infected neonates are clinically well and are indistinguishable from uninfected newborns. Some HIV-1-infected neonates, however, may be ill due to comorbid conditions such as those associated with prematurity, in utero exposure to drugs and alcohol, or congenital infections, mostly cytomegalovirus (09).

Twenty percent of infected children suffer from a severe infantile disease characterized by a progressive encephalopathy and opportunistic infections, with an onset during the first 3 years of life (14; 07; 54). In a large prospective study the cumulative incidence of encephalopathy was 9.9% at 12 months and 13.1% at 24 months, whereas new cases steadily accumulated to reach a cumulative incidence of 16.3% at 84 months. These measurements are associated with other AIDS-defining symptoms (which can also occur in isolation) as well as with an early decrease in the number of circulating CD4 lymphocytes and a high number of viral particles in blood (usually designated as a high "viral load"). These viral particles are present from the first weeks of life (54). Prevalence of HIV encephalopathy has decreased from 40.7% to 18.2% in patients born after 1996, thought to be related to the response of intravenous zidovudine monotherapy. In another prospective study reported in the year 2000, rates were as a low as 1.6% in children on highly active antiretroviral therapy (HAART) therapy, but also relatively higher at 10% regarding rates of arrested HIV encephalopathy. There has been no link between progressive HIV encephalopathy and ADHD or isolated developmental delay (32; 18; 52; 58).

Common initial presentations include cases of Pneumocystis jirovecii pneumonia (PCP), mucosal candidiasis infections, recurrent bacterial infections, failure to thrive or wasting, pulmonary tuberculosis infection, or disseminated herpes zoster infection. Pneumocystis jirovecii pneumonia peaks from 3 to 6 months and is rare within the first month of life. Episodes of oral candidiasis can occur in infants with intact immune systems, but if the infant has severe, recurrent, or persistent infections, then HIV or other immunodeficiency needs to be considered. Recurrent bacterial infections can present as pneumonia, sinusitis, and/or otitis. HIV infected individuals are more likely to develop tuberculosis due to immunologic impairment. Therefore, if a child is diagnosed with tuberculosis, investigation for an underlying HIV infection should be completed. In less severe forms without serious infections, the child may present with a constellation of lymphadenopathy, chronic interstitial lung disease, and persistent parotid gland swelling (50).

Neurologic manifestations of HIV are heterogeneous and may evolve with time. The first abnormal neurologic signs are usually observed between the ages of 3 and 12 months. Motor symptoms are initially noted with both abnormal rigidity of limbs and abnormal postural tone, not unlike those symptoms observed in cerebral palsy. Over time, these symptoms result in spastic paraparesis or quadriparesis, sometimes associated with dystonic posturing and a loss of motor milestones. Thirty percent to 50% of children develop buccolingual dyspraxia: the mouth remains open with abnormal and permanent drooling as well as difficulties with chewing small pieces of food (at appropriate age). Stagnation of cognitively, behaviorally, and socially adaptive skills usually occurs a few months later; patients initially appear comparatively less affected. The pattern of regression is quite variable from 1 child to another, although most decline in a stepwise manner with long plateau periods over 2 to 4 years. After 3 years, affected children are significantly delayed, with small head circumference and severe spastic tetraparesis. Interestingly, the group of infants with subsequent early HIV encephalopathy had a significantly lower head circumference than other HIV-1 infected children (54). It is not unusual for the children to make some cognitive or even motor acquisitions during the plateau periods. Death usually occurs before the age of 5 years.

Eighty percent of infected children have a slowly progressive disease during which, for several years, they remain either asymptomatic or have reversible symptoms. Similarly, there is no severe immune deficiency, and viral load in the blood is low. At school age, the children usually have normal school results and cognitive levels, except for visuospatial and temporal orientation tests, which are more frequently abnormal than in the general population (29; 55; 08). In 1 case series, when compared to healthy controls, HIV-infected pediatric patients did not show worsening of memory or executive function over several years, although history of AIDS defining illness and higher viral load were associated with worse cognitive functioning overall (34).

Prognosis and complications

The risk of development of early and severe form of the disease is highly linked to the viral load in the mother’s peripheral blood at time of birth as well as that of the baby during first weeks of life (13; 27). Viral load influences the time of transmission from mother to fetus as well (most likely) as the time of penetration of the virus into the central nervous system. Severe symptoms (including encephalopathy) occur more frequently in infants, with a heavy virus load in the blood at birth that is tightly linked to maternal status at delivery (Blanche et al 1996; 53; 49). An early treatment with combinations of highly active antiretroviral drugs associated with preventive treatment of opportunistic infections does improve the quality of life of infected children and shows a positive impact of neurodevelopmental trajectory with cognitive and motor impairments. More long-term studies are needed to assess the role of antiretroviral therapy and neurodevelopmental function (30).

There are indeed large inequalities between children in undeveloped countries. The survival rate of infected children was close to 60% at 7 years of age (55) but has been further improved by HAART and efficient preventive treatment of opportunistic infections. A multicenter, prospective birth cohort study from 1985 until 2004 showed statistically significant 10-year survival rates of 94% in children who received HAART therapy compared to 45% in children who did not receive HAART therapy (24).

During the course of HIV-1 infection, several secondary lesions of the CNS can be clinically observed (Table 1). In most cases, all of them occurred after the onset of a severe immune deficiency (at least on a biological background, ie, when CD4 lymphocyte counts were less than 200). Although their description is beyond the scope of this short annotation, 4 clinical situations can be distinguished: (1) acute retinitis and encephalitis, the most frequent etiologic agent being cytomegalovirus; (2) tumor-like lesions (toxoplasmosis, lymphoma, and sarcoma); (3) acute focal lesions sometimes associated with multiple brain infarcts due to aneurysmal lesions of large vessels and multiple areas of vascular obstruction of small cortical vessels; and (4) progressive encephalopathy with abnormal appearance of white matter on MRI. This might be due to a secondary infection with a papovavirus, leading to a progressive multifocal leukoencephalitis, subsequently resulting in a progressive HIV-1-related encephalopathy, but also to infections with mycobacteria, mycoplasma, and viruses such as cytomegalovirus and varicella zoster virus. A firm diagnosis is always difficult to establish, but new techniques involving amplification of genetic material by polymerase chain reaction are of major support.

Development of vascular lesions has been associated with HIV-1 infection, and is thought to result from endothelial dysfunction secondary to chronic inflammation and cytokine imbalances from the infection. This has sometimes been referred to as HIV-associated vasculopathy. Moyamoya syndrome has been described in association with pediatric HIV-1 infection, with evidence of worse outcomes associated with poor HIV control (63).

Cardiovascular problems associated with HIV infection including left ventricular dysfunction and increased left ventricular mass are common and clinically important indicators of survival for children infected with HIV (25).

Table 1. Secondary CNS Complications

CNS infections
	• Common childhood bacterial pathogens • Viral encephalitis and retinitis (CMV, varicella, papovavirus, PML) • Tuberculosis • Parasitic encephalitis (toxoplasmosis)
CNS neoplasms
	• Primary B-cell lymphoma • Lymphoma • Sarcoma
Vascular complications
	• Intracerebral hemorrhage, including subarachnoid hemorrhage • Infarctions
		- Hemorrhagic - Ischemic, large vessel and cortical

Other complications
	• Basal ganglia abnormalities
	• Leukoencephalopathy

Clinical vignette

A 17-month-old female patient accompanied by her mother presented to a medical mission clinic in Port au Prince, Haiti with a 2-month duration of muscle rigidity and general failure to thrive. Although the child had these symptoms for months, the mother brought her in due to altered mental status, or more specifically described by her mother as “my daughter just isn’t herself today”. On exam the child had a small head circumference and generalized muscle rigidity. Upon further questioning, the mother had an unknown HIV status but had 2 previous children who died of a “cerebral palsy”-like illness and multiple infections.

(I) What would be your DDX? Symptoms: muscle rigidity, FFT, AMS, microcephaly
	(A) Infant or child
		• Toxoplasmosis, rubella, cytomegalovirus, herpes, syphilis, Epstein-Barr virus
		• Each of these infections is usually associated with an increased concentration of specific immunoglobulin. Cytomegalovirus can be cultured in blood or urine or identification with PCR. Dark field microscopy, Ab titer, and immunoglobulin-fluorescent treponemal Ab can determine syphilis.
	(B) Late infancy and childhood
		• Severe combined immunodeficiency or variants such as adenosine deaminase or nucleoside phosphorylase deficiency, Omenn syndrome, Bare lymphocyte syndrome, severe combined immune deficiency, and DiGeorge syndrome
(II) What is your next step in diagnosing and treating the child?
	(A) HIV DNA PCR testing and HIV RNA assay are recommended and preferred in children younger than 18 months.
		• Guidelines for the use of antiretroviral agents in pediatric HIV infection: (AIDSinfo.nih.gov)
(III) What is your advice to the mother if she has plans for more children?
	(A) Prophylaxis
		• Goal is to reduce perinatal transmission of HIV disease. It is recommended that all pregnant HIV infected women receive an ART, regardless of CD4 cell count or plasma HIV RNA copy number, to prevent perinatal transmission and for the benefit to maternal health.
	(B) If she becomes pregnant again:
		• Monitor the CD4 cell counts initially and every 3 months during the pregnancy. Plasma viral load should be assessed at 34-36 weeks gestation in order to aid in the decision regarding mode and timing of delivery. If the viral load is greater than 1000 copies/ml near term gestation, the patient should be counseled regarding the benefits of scheduled cesarean section at 38 weeks gestation for prevention of perinatal transmission.
	(C) Other screening tools
		• Drug resistance testing: should be done prior to starting or modifying ART medications in all pregnant women.
		• Monitoring ART toxicity: check CBC, BUN, creatinine, and LFTs
		• Screen for gestational diabetes: usually done at 24-28 weeks but should be done earlier if patient is on protease inhibitors. Protease inhibitors have been shown to be associated with glucose intolerance.
		• Testing for viral hepatitis: both B and C
		• Tuberculosis testing and toxoplasma serology

Biological basis

Etiology and pathogenesis

Human immunodeficiency virus type-1, the etiologic agent of AIDS, is an RNA retrovirus that belongs to the lentivirus subfamily of nononcogenic cytopathic retroviruses.

Principal targets of HIV-1 are the human peripheral blood CD4+ T lymphocytes and monocytes. The loss of CD4 lymphocytes occurs due to direct cytopathic effects of the virus and due to indirect effects on uninfected cells causing cell death. Similarly, HIV causes a cytopathic infection in monocytes; the infection is of a lesser degree, as compared to that not seen in CD4 cells, but it causes monocytes to collapse with one another forming multinucleated giant cells most prominent in the brain parenchyma. It also leads to prominent macrophage activation in various tissues including brain, peripheral nerve, kidney, heart, and other tissues. It is postulated that this massive macrophage activation leads to release of various cytokines that are injurious to neurons in the brain and other cell types in various tissues. The pathogenesis of HIV infection has been best studied in CNS tissues, where it is clear that HIV infects astrocytes other than cells of monocytic lineage. These infected cells also release viral proteins that have toxic properties and hence have been termed “virotoxins.” A number of subcellular mechanisms have been proposed with regards to end organ damage caused by these virotoxins. The virotoxins also lead to the release of chemo-attractant molecules called chemokines, which hone in mononuclear cells into the endorgan, thus setting up a positive feedback loop. HIV-1 is found mostly within cells of the basal ganglia, subthalamic nucleus, substantia nigra, dentate nucleus, and white matter (08).

In children, 1 of the first immunologic abnormalities is impairment of B-cell function, manifested by polyclonal hypergammaglobulinemia, spontaneous B-cell proliferation, and increased in vitro spontaneous production of immunoglobulin. Although the quantity of immunoglobulins is elevated, there are diminished in vivo vaccine responses to both T-cell dependent and independent antigens as well as decreased responses to B-cell mitogens (11; 26). It has been shown that a 25-gene signature in resting memory B cells was able to distinguish H1N1 vaccine responders from nonresponders in HIV patients, as well as a separate 28-gene signature in resting memory B cells distinguishing HIV patients on antiretroviral therapy from healthy controls (19). In vitro studies demonstrate diminished lymphocyte proliferation to B-cell mitogens. The decreased antibody responses predispose these infants and children to serious bacterial infections, which at times may be overwhelming. The B-cell activation may also result in polyclonal polymorphic B-cell lymphoproliferative disorders, such as lymphoid interstitial pneumonitis, parotitis, and unusual B-cell related complications such as B-cell lymphomas.

Increased production of autoantibodies may also result from B-cell dysfunction. Circulating immune complexes, antinuclear antibodies, antibody to double-stranded DNA, red cell antibodies, and antiplatelet antibodies have been reported (26). Hypogammaglobulinemia, another manifestation of B-cell dysfunction, has also been noted in some infants with severe advanced disease.

It is likely that the developmental maturational stage of the nervous and immune system is an important variable when exposed to the direct or indirect effects of the virus. Thymic abnormalities in some fetuses of HIV-1-infected women suggest that an interaction between the virus and the developing fetal immune system may account for the early and severe immune deficiency observed in 15% to 25% of congenitally infected HIV-1 infants. The pathophysiologic mechanism is as yet unclear; both an induction of an immune deficiency in utero and a state of immune tolerance have been proposed (14; 39).

Resting T cells and astrocytes are chronically infected with HIV-1, persisting as stationary cell intermediates from which HIV may be induced. It is unknown whether overall virus burden in peripheral blood reflects the level of compartmentalization of HIV-1 in tissues, and whether differences in relative tissue distribution of the retrovirus may contribute to differences in the clinical outcome. It is possible that the subsequent disease course may be determined in part by tissue distribution as well as the maturity of CD4 cells and bone marrow-derived myelomonocytic cells in the immature host (47). Additional factors, including differential timing of infection, strain of virus, increased sequence diversity, and the high mutation rate of specific HIV-1 genes, may allow the virus to evade immune surveillance and persist within the host. Emergence of genotypic variants with altered biologic activity, such as increased replication rate and cytopathicity, may also increase the pathogenicity of the virus (Conner and Ho 1994; 47).

The pathogenesis and pathophysiology of HIV-1 infection is complex and may lead to a heterogeneous neuropathologic correlation. Table 2 summarizes potential neuropathologic findings in HIV-1 infected patients.

Table 2. Brain Neuropathologic Findings

	Gross
	• Cerebral atrophy of variable degrees
		- Ventricular enlargement - Widening of sulci - Attenuation of deep cerebral white matter

Epidemiology

The worldwide increase in the number of AIDS cases in women of childbearing age is paralleled by an increasing number of children with congenital HIV-1 infection. The true number of HIV-1-infected children is unknown because surveillance systems still rely in most countries on identification of children with clinical manifestations of AIDS. HIV-1 infection in children represents 1% to 3% of reported AIDS cases in industrialized countries but 20% in sub-Saharan Africa (53; 36). In the United States, the number of HIV-1 infections related to mother-to-child transition is less than 2% due to treatment with antiretrovirals in HIV-1 infected pregnant women (Read and Committee on Pediatric AIDS 2007). Maternal coinfection with other sexually transmitted infections increases transmission rate, and this seems to be most significant with multiple sexually transmitted infections or CMV coinfection alone (01; 02).

The most important recent change in pediatric AIDS has been the dramatic reduction of the transmission rate of the virus from mother to offspring. During the natural history of the disease, the transmission rate in large prospective studies ranged from 25% to 30% in the absence of antiretroviral treatment and non-breastfeeding mothers, but can be as high as 50% with prolonged breastfeeding of the infant. It depended on the viral load in peripheral blood of the mother, genetic factors, and, probably, other factors such as sanitary conditions (53; 36; 50). Antiretroviral treatment during the end of pregnancy, at time of delivery, and during the first weeks of the baby’s life has dramatically reduced the transmission rate to less than 2% in most recent studies in industrialized countries. Simplified and less expensive treatments have also been tested with a good efficiency (61).

Prevention

Clearly, the most effective strategy for prevention of congenital HIV-1 transmission is to prevent HIV-1 infection in the mother before pregnancy and indeed in all women of childbearing age. Congenital infection may occur during gestation in the perinatal period, and rarely, via transmission by breast milk postnatally. It remains unclear, however, when most maternal-to-infant transmission occurs (ie, early in pregnancy or around delivery). HIV testing is recommended as early as possible for all pregnant women. Women with high risk factors for HIV infection who were seronegative on initial testing should consider retesting during late pregnancy. Women are at higher risk if they have a history of an HIV infected partner, history of drug abuse, history of sexually transmitted disease, signs or symptoms of acute HIV infection, live in areas with increased incidence of HIV infections in women of childbearing age (≥17 HIV cases per 100,000 person-year), or receive care in facilities with at least 1 diagnosed HIV case per 1000 person-years. If testing was not completed during pregnancy or a woman presents during labor without prenatal care, a rapid HIV antibody test should be completed. A confirmatory HIV test should be drawn as soon as possible if HIV antibody testing is positive (50).

Transmission of HIV-1 from mother to infant can be interrupted with antiretroviral agents or by elective cesarean sections. Use of triple therapy started in pregnancy has increased significantly from less than 1% (1/153) in 1997 to 44% (47/107) in 1999. Exposure to antiretroviral therapy was not associated with prevalence or pattern of congenital abnormalities (P = 0.88) but was associated with reversible anemia in the infant (P < 0.002). The elective cesarean section rate has increased from 10% in 1992 to 71% in 1999/2000. The vertical transmission rate declined from 15.5% by 1994 to 2.6% after 1998. In multivariate analysis, adjusting for maternal CD4 cell count, risk of vertical transmission was reduced by 66% (95% confidence interval, 37% to 82%) with the full 076 regimen and by 60% (95% confidence interval, 33% to 73%) with elective cesarean section delivery. Current recommendations from the American College of Obstetricians and Gynecologists and the Department of Health and Human Services are as follows: (1) HIV infected women with plasma viral loads greater than 1000 copies/mL should be informed of the benefits of elective cesarean sections; (2) elective cesarean delivery should be at the completion of 38 weeks gestation; (3) HIV infected women should receive antiretroviral therapy during pregnancy, which should not be discontinued prior to cesarean delivery; and (4) mothers should receive intravenous zidovudine 3 hours prior to elective cesarean delivery (28). Because HIV can be transmitted via breast milk, HIV infected women are advised against breastfeeding regardless of whether the mother and/or infant are on antiretroviral therapy in the United States. Outside of the United States where replacement feeds are not possible, additional antiretroviral therapies are given during the breastfeeding period to help reduce the risk of transmission while allowing the infant to maintain nutrition (50).

The rate of mother-to-child transmission of HIV-1 ranges from 5% to 10% during pregnancy, 20% to 30% during delivery, and 10% to 20% through breastfeeding in the absence of treatment, whereas it is reduced to less than 2% with antiretroviral therapy during gestation (04).

Differential diagnosis

The infant or child with congenital HIV-1 infection may present with several clinical manifestations. Differential diagnosis, therefore, is dependent on the presenting signs and symptoms as well as the age of the child. In infancy, lymphadenopathy, hepatosplenomegaly, thrombocytopenia, anemia, or leukopenia may occur with other congenital or perinatal infections (toxoplasmosis, rubella, cytomegalovirus, herpes, syphilis, Epstein-Barr virus). Moreover, these infections are often associated with immunologic abnormalities. However, each of these infections is usually associated with an increased concentration of specific immunoglobulin. Additionally, cytomegalovirus may be cultured in urine or blood, and syphilis can be determined by dark field exam, antibody titer, and immunoglobulin-fluorescent treponemal antibody (26).

Later in infancy and in childhood, if the presenting symptoms are chronic, recurrent, or opportunistic infections, the most important and likely diagnosis is an immunodeficiency disorder. Primary, congenital, and secondary immunodeficiency disorders are included in the differential diagnosis. Inherited forms of cellular congenital immunodeficiency diseases that may be considered include severe combined immunodeficiency or variants such as Nezelof syndrome, adenosine deaminase or nucleoside phosphorylase deficiency, Omenn syndrome, Bare lymphocyte syndrome, severe combined immune deficiency with graft-versus-host disease, and DiGeorge syndrome. Other congenital immunodeficiencies include Wiskott-Aldrich syndrome, ataxia-telangiectasia, X-linked lymphoproliferative syndrome, mucocutaneous candidiasis, agammaglobulinemia, and dysgammaglobulinemia. An appropriate history, examination, and immunologic analysis, including HIV-1 serologic testing, can usually rule out these conditions. Hematological disorders that should be considered in the differential diagnosis include neutrophil disorders, reticuloendotheliosis, lymphoma, and idiopathic thrombocytopenic purpura. Secondary immunodeficiencies include malignancy, malnutrition, nephrotic syndrome, protein-losing enteropathy, and severe diarrhea (26).

The differential diagnosis in the infant or child who presents with progressive neurologic dysfunction includes other neurodegenerative diseases (particularly the progressive genetic metabolic diseases, especially if the child has hepatosplenomegaly) and other CNS infections. A thorough history (including family history), physical and neurologic examination, and laboratory studies, including neuroimaging and anti-HIV-1-antibody (for a child greater than 18 months of age), help to make the diagnosis.

Diagnostic workup

The goal of the diagnostic workup is to establish the presence or absence of HIV-1 infection and, if present, to determine the stage of the disease, extent of immune dysfunction, and presence or absence of neurologic involvement. Table 3 demonstrates the recent guidelines for diagnosis of HIV-1 infection in infants and children.

Infants. Newborns and young infants (up to 18 months of age) present special diagnostic challenges. Although the detection of anti HIV-1-specific IgG antibody in peripheral blood in older children and adults is taken as proof of HIV-1 infection, a positive antibody test in a well infant or young child is uninterpretable, as maternal IgG crosses the placenta and may persist for up to 18 months. Thus, a positive IgG antibody test only confirms the seropositivity of the mother. However, a rising titer in the infant may be indicative of HIV-1 infection, as may anti-HIV-1-IgA (IgA is produced by the infant). Direct evidence for HIV-1 infection may be sought by HIV-1 culture, polymerase chain reaction, and assays of circulating p24 in the peripheral blood. Viral load determination is the most sensitive indicator for HIV infection in infants and can be used for diagnosis as early as 5 days postinfection. RNA-PCR-based assays are much more sensitive than the DNA-PCR assays, although both tests are considered the gold standard for diagnosis. Infants with known exposure to HIV-1, either by positive maternal testing or positive rapid antibody test of the infant after birth, are recommended to have HIV-1 DNA-PCR or RNA-PCR assays within the first 14 days of life, between age 1 to 2 months, and between age 3 to 6 months. Two positive HIV-1 DNA-PCR or RNA-PCR assays are required to make the diagnosis. Therefore, if testing reveals a positive result, a repeat test to confirm the diagnosis is recommended (45; Read and Committee on Pediatric AIDS 2007).

Current guidelines no longer recommend ELISA antibody testing at 18 months to confirm absence of HIV infection. However, the authors of a study recommend that serological testing at 18 months should be done to look for the presence or absence of HIV infection in an attempt to increase the diagnosis of HIV in infants born to HIV infected mothers. In their report, and another one by Frange and colleagues, a total of 6 children were found to have delayed diagnosis at 18 months of age (22; 43).

Children. The initial laboratory evaluations of a child over age 18 months who is suspected of having HIV-1 infection should include HIV-1 serologic testing (screening enzyme-linked immunosorbent assay and confirmatory Western blot); a complete blood count; IgA, IgM, IgG levels; and lymphocyte subsets (CD3, CD4, CD8) enumeration. Other routine diagnostic tests, such a chest x-ray, urine analysis, appropriate cultures for pathogens, and a chemistry panel may also be warranted. Most children will have a normal blood count, a positive antibody test, elevated immunoglobulin levels, and variable T-cell abnormalities, dependent on the age of the patient and the stage of disease (03).

Currently, clinical prognostic and therapeutic decisions are based on virologic markers of HIV-1 infection (preferably viral load) and the degree of CD4 lymphopenia relative to normal values for age.

Evaluations of the competence of the immune system, such as lymphocyte proliferative responses to mitogens (phytohemagglutinin, poke weed mitogen) and antigens (tetanus toxoid, Candida, etc), delayed hypersensitivity skin tests, antibody titers to vaccine antigens (eg, tetanus, diphtheria, rubella, Hemophilus), and surrogate markers of immune activation, such a B2 microglobulin assays, may be used to determine immunologic response to therapeutic protocols. Surprisingly enough, the viral load in CSF is usually low in patients with early severe neurologic symptoms, but remains the best predictor of HIV encephalopathy (54; 18).

The evaluation of the HIV-1-infected child for neurologic involvement requires the clinical skills and major diagnostic tools of the neurologist. The approach to the diagnosis of HIV-1-associated CNS disease, including differential diagnosis (secondary complications, confounding comorbid complications), involves a careful medical and developmental history, HIV-1 systemic disease history, current immunologic status, neurologic examination, psychological assessment, and neuroimaging studies (06; 07; 03).

Neuroimaging. CT and MRI findings in infants and children with HIV-1 infection are dependent on the severity of CNS involvement. This can be further complicated by the presence of other opportunistic infections, such as cytomegalovirus and toxoplasmosis, which can also demonstrate intracranial calcifications, microcephaly, hydrocephalus, and atrophy. Table 4 summarizes imaging findings based on neuroanatomical localization. CT and MRI abnormalities are frequent in these patients and can consist of enlargement of the subarachnoid space and ventricles, calcifications of basal ganglia and subcortical areas, and white matter abnormalities (07). In addition to these findings, some children may also develop cerebral aneurysms resulting in subarachnoid hemorrhage or cerebral infarcts. The aneurysms are usually fusiform, involving the major blood vessels that can be seen on vascular imaging studies (40).

Table 3. CDC Surveillance Case Definition for HIV Infection

I. Persons aged at least 18 months and children aged less than 18 months whose mothers were not infected. (Diagnoses can be made based if any of the criteria are met.)
	(A) A multitest algorithm consisting of:
		• A positive (reactive) initial HIV antibody or combination antigen/antibody test • An accompanying or subsequent positive result from a supplemental HIV test different from the initial test
	(B) A positive result of a multitest HIV antibody algorithm from which only the final result was reported (eg, HIV Western blot, immunofluorescence assay, HIV-1/2 type-differentiating rapid antibody immunoassay)
II. Children aged less than 18 months born to mothers with HIV infections or unknown infection status. (Diagnoses can be made if all criteria are met.)
	(A) Positive results on at least 1 specimen (not including cord blood) from any of following HIV virologic tests:
		• HIV-1 NAT (DNA or RNA) • HIV-1 p24 antigen test, including neutralization assay for a child aged more than 1 month • HIV isolation (viral culture), or • HIV nucleotide sequence (genotype)
	(B) The test date (at least the month and year) is known. One or both of the following:
		• Confirmation of the first positive result by another positive result on 1 of the above virologic tests from a specimen obtained on a different date, or • No subsequent negative result on an HIV antibody test, and no subsequent negative result on an HIV NAT before age 18 months
III. Definitively uninfected, perinatal exposure of children less than 18 months
	(A) No positive HIV NAT (RNA or DNA), and
	(B) At least 1 of the following criteria:
		• At least 2 negative HIV NATs from specimens obtained on different dates, both of which were at the age of at least 1 month and 1 of which was at the age of at least 4 months • At least 2 negative HIV antibody tests from specimens obtained on different dates at the age of at least 6 months
IV. Presumptively uninfected, perinatal exposure of children less than 18 months
	(A) Criteria for definitively uninfected with HIV are not met
	(B) At least 1 of the following 4 laboratory criteria is met:
		• At least 2 negative NATs from specimens obtained on different dates, both of which were at the age of at least 2 weeks and 1 of which was at the age of at least 4 weeks • One negative NAT (RNA or DNA) from a specimen obtained at the age of at least 8 weeks • One negative HIV antibody test from a specimen obtained at the age of at least 6 months • If criteria for HIV infection had initially been met by 1 positive HIV NAT test, then it must have been followed by at least 2 negative test results from specimens obtained on different dates, 1 of which is:
			- A NAT test from a specimen obtained at the age of at least 8 weeks, or - An HIV antibody test from a specimen obtained at the age of at least 6 months, and
	(C) No subsequent positive NAT

(17)

Table 4. Neuroimaging Findings

	CT	MRI
Cerebral atrophy	• present in majority of patients • serial studies often show progressive atrophy	• present in majority of patients • serial studies often show progressive atrophy
Basal ganglia	• basal ganglia calcification, ± frontal white matter • present in a subset of patients • serial studies may show progressive "calcification"	• may show abnormal high signal (T2-weighted images at time when CT is "normal") • may show abnormal low signal (T2-weighted images at time when CT shows calcification)
White matter	• white matter hypodensities • serial studies often show progressive changes	• may show abnormal high signal (T2-weighted images)

Management

Antiretroviral therapy. Drugs that treat HIV-1 infection attempt to interfere with the replication of HIV. Targeted points in the growth cycle of the virus include blockage of viral entry (soluble CD4+ preparations), prevention of transcription of RNA to DNA (reverse transcriptase inhibitors), interference with translation (drugs acting on regulatory genes or their proteins), inhibition of assembly (protease inhibitors), release of virus (interferon), and integrase inhibitors.

In clinical trials, children treated with zidovudine had improvement in weight gain and growth, stabilization of CD4 counts, reduction in serum and CSF p24 antigen levels, decrease in immunoglobulin levels, and improvement or stabilization of cognitive function (42; 15; 12). In 2011, a review of 25 trials (22 trials of randomized mothers with follow-ups of their infants and 3 randomized infant trials) assessed the effectiveness of antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection and concluded that triple antiretroviral therapy is the most effective at preventing transmission of HIV from mother to child (51).

Any infant with HIV exposure should receive zidovudine prophylaxis as soon as possible after birth; the goal is within 6 to 12 hours after delivery. Children 25 weeks or older should receive 4 mg/kg orally twice daily for 6 weeks. Zidovudine can be given intravenously if oral medications are not tolerated. In high-risk infants with mothers who did not receive antiretrovirals during pregnancy, 3 doses of nevirapine should be given within the first 48 hours after birth in addition to the zidovudine. The antiretrovirals are generally well tolerated, and the most common side effects are anemia and neutropenia related to the zidovudine (50).

A national observational study in Italy from 2001 to 2011 examined the effects of antiretroviral exposure on birth defects. The study supported that first trimester exposure to antiretroviral therapy did not increase risk of congenital abnormalities in infants (21). An analysis of the Quebec Pregnancy Cohort indicated that major congenital malformations were more common in HIV-positive mothers without antiretroviral exposure compared to the general population, but this was not true for HIV-positive mothers with exposure to antiretroviral therapy (10).

A population analysis study with surveillance data from the UK and Ireland found that pregnant women who received lopinavir/ritonavir (LPV/r) containing ART regimens had a good safety profile, and they were effective for viral suppression during pregnancy. This regimen also had a low associated rate of mother-to-child transmission, which is always the goal (56).

A long-term follow-up of the IMPACCT P1060 randomized trial in 2016 found that in comparison to the nevirapine-based ART, LPV/r-based ART was associated with fewer virologic failures or deaths over time in an extended 5-year follow-up (05). Short-term superiority of the nevirapine arm in CD4 percentage recovery did not persist beyond 1 year. This evidence provides support for the continued use of LPV/r-based regimens as part of first-line treatment of pediatric HIV.

Outcomes

The PHACS SMARTT study evaluated the safety of in utero exposure to antiretroviral (ARV) medications and found that overall the data is generally reassuring, with minimal evidence for serious adverse events. However, they did find increased rate of premature delivery and selected birth defects with certain antiretroviral exposure. Specifically, atazanavir exposure was associated with lower language achievement at 1 year, a 2-fold risk of congenital anomalies, and was known to increase unconjugated bilirubin levels in the blood. Tenofovir exposure was associated with decreased newborn bone mineral content and reduced growth at 1 year. Some subclinical cardiac abnormalities were also noted, but it is unclear if these will predict a future premature heart disease (57).

A French perinatal multicenter cohort of 13,124 live births from HIV infected mothers with HAART found a significant association between first trimester zidovudine exposure and congenital heart defects, specifically a prevalence of 2.3% (58% VSD, 18% ASD cases). In a U.S. prospective cohort (SMARTT study) of 2580 HIV exposed but uninfected children, Williams and colleagues looked at first trimester exposure to antiretrovirals and found that the prevalence of congenital anomalies was 6.8% (62; 59).

The Pediatric AIDS-Defining Cancer Project Working Group found that in a study of 24,991 children in Africa, Europe, and Asia, HIV infected children from sub-Saharan Africa but not those from other geographical regions were at high risk for developing Kaposi sarcoma after cART initiation. Therefore, they suggest that early cART initiation in these children may help reduce Kaposi sarcoma risk (41).

Hrapcak and colleagues found that there is an overall 24% prevalence of hearing loss (which is 82% conductive hearing loss) in children aged 4 to 14 years with congenital HIV in Lilongwe, Malawi (23). Although this amount is lower than previous reports, it is still significant. The authors state that there is urgent need for improved screening tools, identification, and treatment of hearing to prevent adverse effects on school functioning and quality of life. Suggestions include more frequent ear assessments and hearing evaluations than for children without congenital HIV infection. Another study found similar rates of hearing loss when tested by objective measures between HIV-positive children and healthy controls (37), despite significantly higher numbers of self-reported hearing loss in HIV-positive patients.

Future directions of therapeutics include antilatency drugs, which work by activating viral production from latently infected cells to purge and clear HIV-1 reservoirs. Martinez-Bonet and colleagues discuss the possibility of the role of antilatency drugs in chronically HIV infected pediatric patients (35).

In a review article discussing the challenges of eliminating pediatric HIV infection, Luzuriaga and Mofenson also commented that additional research needs to be done to improve methods of early diagnosis in resource-limited settings and methods to define the size and distribution of the latent HIV-1 reservoir in children more actively (33).

References

01: Acosta LMW, Gonçalves TR, Barcellos NT. HIV and syphilis coinfection in pregnancy and vertical HIV transmission: a study based on epidemiological surveillance data [Article in Portuguese]. Rev Panam Salud Publica 2016;40(6):435-42. PMID 28718492
02: Adachi K, Xu J, Yeganeh N, et al. Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission. PLoS One 2018;13(1):e0189851. PMID 29304083
03: Agency for Health Care Policy and Research. Evaluation and management of early HIV infection. Clinical practice guideline No. 7. AHCPR Publication No. 94-0572. U.S. Department of Health and Human Services, January 1994.
04: Aldrovandi, GM, Kuhn L. What babies and breasts can teach us about natural protection from HIV infection. J Infect Dis 2010;202 Suppl 3:S366-70. PMID 20887226
05: Barlow-Mosha L, Angelidou K, Lindsey J, et al. Nevirapine vs Lopinavir/ritonavir based antiretroviral therapy in HIV infected infants and young children: long-term follow-up of the IMPAACT P1060 Randomized Trial. Clin Infect Dis 2016;63(8):1113-21. PMID 27439527
06: Belman AL. AIDS and pediatric neurology. In: Bodensteiner J, editor. Pediatric neurology. Neurol Clin North Am 1990;8:571-603.
07: Belman AL. AIDS and the child's central nervous system. Pediatr Clin North Am 1992;39:691-714. PMID 1635802
08: Belman AL. HIV-1 infection and AIDS. Neurol Clin 2002;20(4):983-1011. PMID 12616678
09: Belman AL, Muenz LR, Marcus JC, et al. Neurologic status of human immunodeficiency virus 1-infected infants and their controls: a prospective study from birth to 2 years. Pediatrics 1996;98:1109-18. PMID 8951261
10: Berard A, Sheehy O, Zhao JP, et al. Antiretroviral combination use during pregnancy and the risk of major congenital malformations. AIDS 2017;31(16):2267-77. PMID 28806195
11: Bernstein LJ, Ochs HD, Wedgewood RJ, Rubinstein A. Defective humoral immunity in pediatric acquired immunodeficiency syndrome. J Pediatr 1985;107:352-7. PMID 4032129
12: Blanche S, Duliege AM, Navarette MS, et al. Low dose zidovudine in children with human immunodeficiency virus infection acquired in the perinatal period. Pediatrics 1991;88:364-70. PMID 1861941
13: Blanche S, Mayaux MJ, Rouzioux C, et al. Relation of the course of HIV infection in children to the severity of the disease in their mothers at delivery. N Engl J Med 1994;330:308-12. PMID 7904046
14: Blanche S, Tardieu M, Duliege AM, et al. Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection: evidence for a bimodal expression of clinical and biological symptoms. Am J Dis Child 1990;144:1210-5. PMID 1978551
15: Brouwers P, Moss H, Wolters P, et al. Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. J Pediatr 1990;117:980-5. PMID 2246704
16: Centers for Disease Control. Unexplained immunodeficiency and opportunistic infections in infants: New York, New Jersey, California. MMWR 1982;31:665-7.
17: Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection–United States, 2014. MMWR Recomm Rep 2014;63(RR-03):1-10. PMID 24717910
18: Chiriboga CA, Fleishman S, Champion S, Gaye-Robinson L, Abrams EJ. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J Pediatr 2005;146(3):204-7. PMID 15756229
19: Cotugno N, De Armas L, Pallikkuth S, et al. Perturbation of B cell gene expression persists in HIV-infected children despite effective antiretroviral therapy and predicts H1N1 response. Front Immunol 2017;8:1083. PMID 28955330
20: European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet 1992;399:1007-12. PMID 1349050
21: Floridia M, Mastroiacovo P, Tamburrini E, et al. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG 2013;120(12):1466-75. PMID 23721372
22: Frange P, Burgard M, Lachassinne E, et al. Late post-natal HIV infection in children born to HIV-1 infected mothers in a high-income country. AIDS 2010;24(11):1771-6. PMID 20479638
23: Hrapcak S, Kuper H, Bartlett P, et al. Hearing loss in HIV-infected children in Lilongwe, Malawi. PLoS One 2016;11(8):e0161421. PMID 27551970
24: Kapogiannis BG, Soe MM, Nesheim SR, et al. Mortality trends in US perinatal AIDS Collaborative Transmission Study (1986-2004). Clin Infect Dis 2011;53(10):1024-34. PMID 22002982
25: Keesler MJ, Fisher SD, Lipshultz SE. Cardiac manifestations of HIV infection in infants and children. Ann N Y Acad Sci 2001;946:169-78. PMID 11762985
26: Koup RA, Wilson CB. Clinical immunology of HIV-infected children. In: Pizzo PA, Wilfert CM, editors. Pediatric AIDS: the challenge of HIV infection in infants, children and adolescents. 2nd ed. Baltimore: Williams & Wilkins, 1994:129-2157.
27: Lambert G, Thea DM, Pliner V, et al. The New York City Perinatal HIV Transmission Collaborative Study Group. Effect of maternal CD4+ cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection. J Pediatr 1997;130:890-7. PMID 9202610
28: Legardy-Williams JK, Jamieson DJ, Read JS. Prevention of mother-to-child transmission of HIV-1: the role of cesarean delivery. Clin Perinatol 2010;37(4):777-85. PMID 21078450
29: Levenson RL Jr, Mellins CA, Zawadzki R, Kairam R, Stein Z. Cognitive assessment of human immunodeficiency virus exposed children. Am J Dis Child 1992;146:1479-83. PMID 1456264
30: Lindsey JC, Malee KM, Brouwers P, Hughes MD, PACTG 219C Study Team. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics 2007;119(3):e681-93. PMID 17296781
31: Livingston EG. Management of HIV in pregnancy. Curr Womens Health Rep 2002;2:245-52. PMID 12150750
32: Lobato MN, Caldwell B, Ng P, Oxtoby MJ, and the Pediatric Spectrum of Disease Clinical Consortium. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. J Pediatr 1995;126:710-5. PMID 7751993
33: Luzuriaga K, Mofenson L. Challenges in the elimination of pediatric HIV-1 infection. N Engl J Med 2016;374(8):761-70. PMID 26933850
34: Malee KM, Chernoff MC, Sirois PA, et al. Impact of perinatally acquired HIV disease upon longitudinal changes in memory and executive functioning. J Acquir Immune Defic Syndr 2017;75(4):455-64. PMID 28481783
35: Martinez-Bonet M, Clemente MI, Serramia MJ, et al. Immunological and pharmacological strategies to reactivate HIV-1 from latently infected cells: a possibility for HIV-1 paediatric patients? J Virus Erad 2015;1(3):148-52. PMID 27482406
36: Misrahi M, Teglas JP, N’Go N, et al. The French Pediatric HIV infection Study Group. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. JAMA 1998;279:277-80. PMID 9450710
37: Nakku D, Nyaiteera V, Llowet E, et al. HIV status and hearing loss among children between 6 and 12 years of age at a large urban health facility in south western Uganda. Int J Pediatr Otorhinolaryngol 2017;101:172-7. PMID 28964291
38: Oleske J, Minnefor A, Cooper R, et al. Immune deficiency syndrome in children. JAMA 1983;249:2345. PMID 6834633
39: Papiernik M, Brossard Y, Mulliez N, et al. Thymic abnormalities in fetuses aborted from human immunodeficiency virus type 1 seropositive women. Pediatrics 1992;89:297-301. PMID 1734399
40: Patsalides AD, Wood LV, Atac GK, Sandifer E, Butman JA, Patronas NJ. Cerebrovascular disease in HIV-infected pediatric patients: neuroimaging findings. AJR Am J Roentgenol 2002;179:999-1003. PMID 12239054
41: Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD, and COHERE in EuroCoord. Kaposi sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from sub-Saharan Africa, Europe and Asia. Clin Infect Dis 2016;63(9):1245-53. PMID 27578823
42: Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988;319:889-96. PMID 3166511
43: Puertolas MV, Bolton MT, Steele RW. Late ELISA testing in infants born to HIV-positive mothers. Clin Pediatr (Phila) 2016;55(7):673-6. PMID 26294760
44: Read JS, Committee on Pediatric AIDS, American Academy of Pediatrics. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics 2007;120(6):e1547-62. PMID 18055670
45: Reisler RB, Thea DM, Pliner V, et al. Perinatal AIDS Collaborative Transmission Studies (PACTS) members. Early detection of reverse transcriptase activity in plasma of neonates infected with HIV-1: a comparative analysis with RNA-based and DNA-based testing using polymerase chain reaction. J Acquir Immune Defic Syndr 2001;26:93-102. PMID 11176273
46: Rogers MF, Ou CY, Rayfield M, et al. Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus infections in infants born to seropositive mothers. N Engl J Med 1989;320:1649-54. PMID 2725615
47: Rosenberg ZF, Fauci AS. Immunopathology and pathogenesis of HIV infection. In: Pizzo PA, Wilfert CM, editors. Pediatric AIDS: the challenge of HIV infection in infants, children and adolescents. 2nd ed. Baltimore: Williams & Wilkins, 1994:115-27.
48: Rubinstein A. Acquired immunodeficiency syndrome in infants. Am J Dis Child 1983;137:825-7. PMID 6310988
49: Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997;336:1337-42. PMID 9134873
50: Siberry GK. Preventing and managing HIV Infection in infants, children, and adolescents in the United States. Pediatr Rev 2014;35(7):268-86. PMID 24986927
51: Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2011;(7):CD003510. PMID 21735394
52: Smith R, Malee K, Leighty R, et al. Effects of perinatal HIV infections and associated risk factors on congenital development among young children. Pediatrics 2006;117(3):851-62. PMID 16510667
53: Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9. PMID 8965861
54: Tardieu M, Le Chenadec J, Persoz A, et al. HIV-1–related encephalopathy in infants compared with children and adults. Neurology 2000;54:1089-95. PMID 10720279
55: Tardieu M, Mayaux MJ, Seibel N, et al. Cognitive assessment of school age children infected with maternally transmitted human immunodeficiency virus type 1. J Pediatr 1995;126:375-9. PMID 7869195
56: Tookey PA, Thorne C, Van Wyk J, Norton M. Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland. BMC Infect Dis 2016;16:65. PMID 26847625
57: Van Dyke RB, Chadwick EG, Hazra R, Williams PL, Seage GR 3rd. The PHACS SMARTT Study: assessment of the safety of in utero exposure to antiretroviral drugs. Front Immunol 2016;7:199. PMID 27242802
58: Van Rie A, Dow A, Mupuala A, Stewart P. Neurodevelopmental trajectory of HIV-infected children accessing care in Kinshasa, Democratic Republic of Congo. J Acquir Immune Defic Syndr 2009;52(5):636-42. PMID 19730268
59: Vannappagari V, Albano JD, Koram N, Tilson H, Scheuerle AE, Napier MD. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry. Eur J Obstet Gynecol Reprod Biol 2016;197:6-10. PMID 26687320
60: Wara DW, Luzuriaga K, Martin NL, Sullivan JL, Bryson YJ. Maternal transmission and diagnosis of human immunodeficiency virus during infancy. In: Lyman WD, Rubinstein A, editors. Pediatric AIDS: Clinical, Pathologic, and Basic Science Perspectives. New York. Ann N Y Acad Sci, 1993;693:14-9.
61: Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjian, Côte d'Ivoire: a randomised trial. Lancet 1999;353:781-5. PMID 10459958
62: Williams PL, Crain MJ, Yildirim C, et al. Congenital anomalies and in utero antiretroviral exposure in HIV-exposed uninfected Infants. JAMA Pediatr 2015;169(1):48-55. PMID 25383770
63: Yamanaka J, Nozaki I, Tanaka M, et al. Moyamoya syndrome in a pediatric patient with congenital human immunodeficiency virus type 1 infection resulting in intracranial hemorrhage. J Infect Chemother 2018;24(3):220-3. PMID 29138020

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Dana Vanino MD

Dr. Vanino of Geisinger Medical Center has no relevant financial relationships to disclose.
See Profile
Lucie Henry MS

Ms. Henry of Geisinger Medical Center has no relevant financial relationships to disclose.
See Profile
Kelly J Baldwin MD

Dr. Baldwin of Geisinger Medical Center has no relevant financial relationships to disclose.
See Profile

Editor

Karen L Roos MD FAAN

Dr. Roos of Indiana University School of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

Anita Belman MD (original author), Avindra Nath MD, Marc Tardieu MD, Meihui Ma MD, Allyson Bazarsky DO, Dana Vanino MD, and Lucie Henry MS

Patient Profile

Age range of presentation: 0-01 month

01-23 months

02-05 years

06-12 years

13-18 years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Psychosis: 298.9

Acquired immunodeficiency virus, AIDS: 042.9

Demyelinating disease of central nervous system unspecified: 341.9

Encephalopathy not elsewhere classified: 348.3

Lack of expected normal physiological development in childhood: 783.4

Unspecified disorders of nervous system: 349.9
ICD-10: Psychosis: F29

Acquired immunodeficiency virus, AIDS: B24

Demyelinating disease of central nervous system unspecified: G37.9

Encephalopathy not elsewhere classified: G93.4

Lack of expected normal physiological development in childhood: R62.9

Unspecified disorders of nervous system: G96.9

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Congenital HIV-1 infection

Associated Disorders

Bacterial infections
Candidiasis of the trachea, bronchi, lungs, esophagus
Coccidioidomycosis
Cryptococcosis
Cryptosporidiosis
- Cytomegalovirus disease
- Cytomegalovirus retinitis
- HIV encephalopathy
- HIV-associated progressive encephalopathy
- Chronic herpes simplex ulcer or pneumonitis or esophagitis
- Isosporiasis
- Kaposi sarcoma
- Lymphoid interstitial pneumonitis
- Lymphoma
- Mycobacterium avium complex
- Mycobacterium tuberculosis or acid-fast infection
- Pneumonia
- Pneumocystis carinii pneumoniae
- Progressive multifocal leukoencephalopathy
- Toxoplasmosis of brain
- Wasting syndrome caused by HIV

Differential Diagnosis

toxoplasmosis
rubella
cytomegalovirus
herpes
syphilis
- Epstein-Barr virus
- primary immunodeficiency virus
- congenital immunodeficiency virus
- secondary immunodeficiency virus
- cellular congenital immunodeficiency virus
- Nezlof syndrome
- adenosine deaminase deficiency
- nucleoside phosphorylase deficiency
- Omenn syndrome
- bone lymphocyte syndrome
- severe combined immunodeficiency with graft-versus-host disease
- DiGeorge syndrome
- Wiskott-Aldrich syndrome
- ataxia-telangiectasia
- x-linked lymphoproliferative syndrome
- mucocutaneous candidiasis
- agammaglobulinemia
- dysgammaglobulinemia
- neutrophil disorder
- reticuloendotheliosis
- lymphoma
- idiopathic thrombocytopenia
- purpura
- malignancy
- malnutrition
- nephrotic syndrome
- protein-losing enteropathy
- severe diarrhea
- other neurodegenerative disorders
- other CNS infections

Also Relevant

Acquired human cytomegalovirus
AIDS and HIV: neurologic manifestations and complications
Congenital cytomegalovirus
Congenital syphilis
HIV-associated dementia
- Peripheral nerve complications of HIV-1 infection
- Vaccines for neurologic disorders

Congenital HIV-1 infection

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Table 1. Secondary CNS Complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 2. Brain Neuropathologic Findings

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Table 3. CDC Surveillance Case Definition for HIV Infection

Table 4. Neuroimaging Findings

Management

Outcomes

Special considerations

Pregnancy

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Prion diseases

Rabies

Malaria

Breath-holding spells

Neuropathies associated with cytomegalovirus infection

Genital herpes: neurologic complications

Neurocysticercosis

This is an article preview.
Start a Free Account
to access the full version.